top of page

Gruppen-Feed

Hier sind alle Gruppen und Beitrรคge zu finden.


Beitrag aus einer empfohlenen Gruppe:

49 Ansichten

Beitrag aus einer empfohlenen Gruppe:

47 Ansichten

Beitrag aus einer empfohlenen Gruppe:

48 Ansichten

Beitrag aus einer empfohlenen Gruppe:

Ileana G
vor 16 Tagen ยท hat einen Beitrag in Zug Pharma Group verรถffentlicht.

๐ŸŒŸ ๐‚๐จ๐ฎ๐ง๐ญ๐๐จ๐ฐ๐ง ๐ญ๐จ ๐ญ๐ก๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ! Itโ€™s time to unveil the ๐ฆ๐š๐ข๐ง ๐ฉ๐ฅ๐ž๐ง๐š๐ซ๐ฒ of the ๐™๐ฎ๐ ย ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”.


AI, robotics and quantum computing could unlock trillions in productivity gains for global healthcare over the next fifteen years. But turning technological potential into real impact is the challenge.


Thatโ€™s the focus of this yearโ€™s main plenary:

๐…๐ฎ๐ญ๐ฎ๐ซ๐ž ๐‘๐ž๐š๐๐ฒ: ๐Œ๐š๐ค๐ข๐ง๐  ๐ˆ๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง ๐๐š๐ฒ ๐Ž๐Ÿ๐Ÿ


Bringing together three senior leaders with very different vantage points, the session will explore whatโ€™s genuinely different now, where healthcare innovation is heading and, most importantly, what organisations can do about it.


๐ŸŽ™๏ธ ๐ƒ๐ซ. ๐Ž๐ฅ๐ข๐ฏ๐ž๐ซ ๐„๐ข๐ญ๐ž๐ฅ๐ฐ๐ž๐ข๐ง | ๐๐š๐ซ๐ญ๐ง๐ž๐ซ, ๐‡๐ž๐š๐ฅ๐ญ๐ก & ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ, ๐Ž๐ฅ๐ข๐ฏ๐ž๐ซ ๐–๐ฒ๐ฆ๐š๐ง


49 Ansichten

Beitrag aus einer empfohlenen Gruppe:

38 Ansichten

Beitrag aus einer empfohlenen Gruppe:

Ileana G
vor 18 Tagen ยท hat einen Beitrag in Zug Pharma Group verรถffentlicht.

๐ŸŒŸ ๐‚๐จ๐ฎ๐ง๐ญ๐๐จ๐ฐ๐ง ๐ญ๐จ ๐ญ๐ก๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ! Hereโ€™s another look at one of the workshops powering the ๐™๐ฎ๐  ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”.


What happens when you bring together AI innovators and the experience of the Life Science community?


At the Zug Life Sciences Summit 2026, our ๐’๐ญ๐š๐ซ๐ญ-๐”๐ฉ ๐ƒ๐ž๐ง: ๐๐ข๐จ๐ญ๐ž๐œ๐ก & ๐€๐ˆ ๐ญ๐จ๐จ๐ฅ๐ฌย will bring three companies to the stage, each presenting their innovation and a real challenge to the room:


๐€๐๐ซ๐ฎ๐ฅ๐ž โ€“ Smarter digital marketing and audience targeting with AI.

๐„๐œ๐จ๐ฌ๐ฒ๐ฌ๐ญ๐ž๐ฆ ๐ˆ๐ง๐ญ๐ž๐ฅ๐ฅ๐ข๐ ๐ž๐ง๐œ๐ž โ€“ Turning pharma intelligence into interactive ecosystem maps.

๐€๐œ๐จ๐๐ข๐ฌ ๐€๐† โ€“ Automating document, quality and regulatory workflows with AI.


45 Ansichten

Beitrag aus einer empfohlenen Gruppe:

38 Ansichten

Beitrag aus einer empfohlenen Gruppe:

Ileana G
vor 22 Tagen ยท hat einen Beitrag in Zug Pharma Group verรถffentlicht.

๐ŸŒŸย ๐‚๐จ๐ฎ๐ง๐ญ๐๐จ๐ฐ๐ง ๐ญ๐จ ๐ญ๐ก๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ! Hereโ€™s another look at one of the workshops powering the ๐™๐ฎ๐  ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”.


Pharma companies are investing heavily in AI, but are these investments translating into measurable business value โ€” or simply increasing costs?


At the Zug Life Sciences Summit 2026, Nick Starritt and Irene Schindeleย from Mercerย and Oliver Wymanย will host an interactive workshop:


๐€๐ซ๐žย ๐˜๐จ๐ฎ ๐’๐œ๐š๐ฅ๐ข๐ง๐  ๐€๐ˆ โ€” ๐จ๐ซ ๐‰๐ฎ๐ฌ๐ญ ๐’๐œ๐š๐ฅ๐ข๐ง๐  ๐‚๐จ๐ฌ๐ญ? ๐“๐ฎ๐ซ๐ง๐ข๐ง๐  ๐–๐จ๐ซ๐ค๐Ÿ๐จ๐ซ๐œ๐ž ๐€๐๐จ๐ฉ๐ญ๐ข๐จ๐ง ๐ข๐ง๐ญ๐จ ๐Œ๐ž๐š๐ฌ๐ฎ๐ซ๐š๐›๐ฅ๐ž ๐€๐ˆ ๐‘๐Ž๐ˆ


Drawing on Mercerโ€™s Global Talent Trends 2026 and experience from large-scale AI transformations, this session will explore how leadership, workforce readiness and organisational adoption can turn AI investment into sustainable business value.


Expect:


38 Ansichten

Beitrag aus einer empfohlenen Gruppe:

Ileana G
vor 24 Tagen ยท hat einen Beitrag in Zug Pharma Group verรถffentlicht.

๐ŸŒŸ ๐‚๐จ๐ฎ๐ง๐ญ๐๐จ๐ฐ๐ง ๐ญ๐จ ๐ญ๐ก๐ž ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ! Here is a first look at another workshop powering the ๐™๐ฎ๐  ๐‹๐ข๐Ÿ๐ž ๐’๐œ๐ข๐ž๐ง๐œ๐ž๐ฌ ๐’๐ฎ๐ฆ๐ฆ๐ข๐ญ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”.


Europe is at a critical juncture in the global biotech race. With competition for investment, talent and innovation intensifying, how can Europe turn its world-class science into commercial success?


At the Zug Life Sciences Summit 2026, ๐‚๐จ๐ฏ๐ข๐ง๐ ๐ญ๐จ๐ง & ๐๐ฎ๐ซ๐ฅ๐ข๐ง๐  ๐‹๐‹๐ will host an interactive workshop:


๐ˆ๐ง๐ฏ๐ž๐ฌ๐ญ๐ข๐ง๐  ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž๐š๐ง ๐๐ข๐จ๐ญ๐ž๐œ๐ก ๐ˆ๐ง๐ง๐จ๐ฏ๐š๐ญ๐ข๐จ๐ง


Drawing on perspectives across regulation, investment and market access, this session will explore what Europe needs to remain globally competitive: from the European Biotech Act and new sources of international capital to creating the right environment for biotech companies to grow, scale and invest.


Expect:


31 Ansichten
bottom of page